cilengitide has been researched along with Astrocytoma, Grade IV in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (25.00) | 29.6817 |
| 2010's | 29 (72.50) | 24.3611 |
| 2020's | 1 (2.50) | 2.80 |
| Authors | Studies |
|---|---|
| Brancaccio, D; Cavallini, C; Cerofolini, L; Costa, B; Da Settimo, F; Daniele, S; Di Leva, FS; Di Maro, S; Fragai, M; Giuntini, S; Kessler, H; La Pietra, V; Luchinat, C; Marinelli, L; Martini, C; Merlino, F; Novellino, E; Piccarducci, R; Reichart, F; Taliani, S; Tomassi, S | 1 |
| Alalami, H; Bannykh, S; Fan, X; Hu, J | 1 |
| Camargo, MF; Cheresh, DA; Chneiweiss, H; Cosset, É; Dietrich, PY; Dutoit, V; Elliott, K; Gomez, G; Guan, KL; Ilmjärv, S; Krause, KH; Mischel, PS; Moo, JS; Moroishi, T; Preynat-Seauve, O; Reiss, A; Sarkaria, JN; Seguin, L; von Schalscha, T; Weis, SM | 1 |
| Campian, JL; Chang, X; Fergus, S; Hallahan, D; Huang, J; Hui, C; Lin, AJ; Mullen, D; Rao, YJ; Rudra, S; Samson, P; Thotala, D; Tsien, C; Yang, D | 1 |
| An, X; Ge, H; Gu, T; Guo, L; Jiang, Q; Meng, X; Ning, X; Shan, X; Zhang, L | 1 |
| Classen, CF; Linnebacher, M; Mullins, CS; Schneider, B; Schubert, J | 1 |
| Date, I; Ichikawa, T; Kurozumi, K; Onishi, M | 1 |
| Homicsko, K; Hottinger, AF; Stupp, R | 1 |
| Clément, PM; Eisele, AC; Eisele, G; Krex, D; Neyns, B; Nikkhah, G; Ochsenbein, A; Picard, M; Schlegel, U; Simon, M; Stupp, R; Tabatabai, G; Tonn, J; Weller, M; Wick, A; Wick, W | 1 |
| Chinot, OL | 1 |
| Adamska, K; Aldape, KD; Brandes, AA; Erridge, SC; Gorlia, T; Grujicic, D; Gupta, T; Hau, P; Hegi, ME; Herrlinger, U; Hicking, C; Hong, YK; Kim, CY; Kortmann, RD; Lhermitte, B; Markivskyy, A; McBain, C; Nabors, LB; Nam, DH; Perry, J; Picard, M; Pietsch, T; Rao, N; Reardon, DA; Schnell, O; Shen, CC; Steinbach, JP; Stupp, R; Taphoorn, MJ; Tarnawski, R; Thurzo, L; Tonn, JC; van den Bent, MJ; Weller, M; Weyerbrock, A; Wick, W; Wiegel, T | 1 |
| Ameratunga, MS; Grant, R; Khasraw, M; Pavlakis, N; Wheeler, H | 1 |
| Ashby, L; Depenni, R; Fink, KL; Grujicic, D; Hegi, ME; Hicking, C; Lhermitte, B; Mazurkiewicz, M; Mikkelsen, T; Nabors, LB; Nam, DH; Perry, JR; Picard, M; Reardon, DA; Salacz, M; Tarnawski, R; Zagonel, V | 1 |
| Ahluwalia, MS; Batchelor, TT; Duda, DG; Gerstner, ER; Grossman, S; Jain, RK; Kaley, TJ; Levine, MA; Mikkelsen, T; Nabors, BL; Olson, JJ; Wen, PY; Ye, X | 1 |
| Bunse, L; Burghardt, I; Gramatzki, D; Hao, N; Leske, H; Platten, M; Roth, P; Rushing, EJ; Silginer, M; Weller, M | 1 |
| Anderson, HJ; Galileo, DS | 1 |
| Bady, P; Goodman, SL; Gorlia, T; Hegi, ME; Hicking, C; Hong, YK; Leske, H; Moch, H; Nabors, LB; Perry, J; Picard, M; Roth, P; Rushing, E; Straub, J; Stupp, R; Weller, M; Wick, W | 1 |
| Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H | 1 |
| Gramatzki, D; Roth, P; Seystahl, K; Weller, M | 1 |
| Aryal, MP; Bagher-Ebadian, H; Brown, SL; Cabral, G; Elmghirbi, R; Ewing, JR; Keenan, KA; Nagaraja, TN; Panda, S | 1 |
| Mikkelsen, T; Nabors, LB; Reardon, DA; Stupp, R | 1 |
| Burdette-Radoux, S; Cloughesy, TF; Dropcho, EJ; Fink, KL; Glantz, M; Mikkelsen, T; Nabors, LB; Nippgen, J; O'Neill, A; Picard, M; Plotkin, S; Raizer, JJ; Ravin, P; Reardon, DA; Rich, KM; Schiff, D; Shapiro, WR; Wittemer, SM | 1 |
| Bokemeyer, C; Celik, I; Fiedler, W; Hauschild, J; Nippgen, J; Oliveira-Ferrer, L; Schuch, G | 1 |
| Berens, ME; Brodie, C; Brown, SL; Finniss, S; Goodman, SL; Hahn, D; Lemke, N; Mikkelsen, T; Nelson, K; Neuteboom, B; Rennert, JL | 1 |
| Chamberlain, MC | 2 |
| Nabors, B; Reardon, D; Stupp, R; Weller, M | 1 |
| Desideri, S; Fisher, J; Grossman, SA; Nabors, LB; Piantadosi, S; Rosenfeld, M; Ye, X | 1 |
| Clement, PM; Dietrich, PY; Diserens, AC; Goldbrunner, R; Grabenbauer, GG; Hegi, ME; Hermisson, M; Hicking, C; Krueger, S; Neyns, B; Ochsenbein, AF; Pica, A; Picard, M; Pietsch, T; Schlegel, U; Simon, M; Stupp, R; Tonn, JC; Weller, M | 1 |
| Carter, A | 1 |
| Nabors, LB; Neyns, B; Reardon, DA; Stupp, R; Tonn, JC; Weller, M | 1 |
| Chang, S; Cloughesy, T; Deangelis, LM; Gilbert, MR; Kuhn, J; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, M; Wen, PY | 1 |
| Batchelor, T; Brem, S; Fisher, JD; Grossman, SA; Hegi, ME; Lesser, G; Mikkelsen, T; Nabors, LB; Olsen, J; Peereboom, D; Rosenfeld, MR; Ye, X | 1 |
| Caporello, P; Enrici, RM; Minniti, G; Scaringi, C | 1 |
| DeWitt, JP; Han, JH; Kim, B; Kim, CY; Kim, SK; Kim, YH; Lee, JE; Lee, JK; Oh, CW | 1 |
| Goodman, SL; Hasenbach, K; Maurer, G; Moch, H; Roth, P; Schraml, P; Silginer, M; Tabatabai, G; Thies, S; Tritschler, I; Weller, M | 1 |
| Akella, NS; Cloud, GA; Grossman, S; Hochberg, FH; Mikkelsen, T; Nabors, LB; Twieg, DB | 1 |
| Tucker, GC | 1 |
| Bu, XY; Gonzales-Gomez, I; Khankaldyyan, V; Laug, WE; McComb, JG; Yamada, S | 1 |
| Barsky, L; Gilles, FH; Gonzalez-Gomez, I; Laug, WE; Shimada, H; Stins, M; Suzuki, A; Taga, T; Weinberg, KI | 1 |
7 review(s) available for cilengitide and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Cell Adhesion; Combined Modality Therapy; Glioblastoma; Humans; Integrin alphaVbeta3; Neoplasm Invasiveness; Neoplasm Proteins; Neovascularization, Pathologic; Snake Venoms; Vascular Endothelial Growth Factor A | 2013 |
Standards of care and novel approaches in the management of glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Cancer Vaccines; Electric Stimulation Therapy; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Immunotherapy; Quinazolines; Snake Venoms; Standard of Care; Vaccines, Subunit | 2014 |
Antiangiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Hypertension; Irinotecan; Lomustine; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Proteinuria; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide | 2014 |
Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.
Topics: Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Neovascularization, Pathologic; Snake Venoms; Temozolomide | 2016 |
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.
Topics: Animals; Antineoplastic Agents; Central Nervous System Neoplasms; Clinical Trials as Topic; Drug Evaluation, Preclinical; Glioblastoma; Humans; Integrins; Models, Molecular; Oligopeptides; Protein Binding; Snake Venoms; Treatment Outcome | 2008 |
Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Integrins; Mice; Rats; Signal Transduction; Snake Venoms; Temozolomide | 2012 |
Integrins: molecular targets in cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Central Nervous System Neoplasms; Clinical Trials as Topic; Glioblastoma; Humans; Indoles; Integrins; Melanoma; Neoplasms; Porphyrins; Skin Neoplasms; Snake Venoms; Sulfonamides | 2006 |
11 trial(s) available for cilengitide and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Snake Venoms; Temozolomide; Treatment Outcome | 2014 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Detection of Cancer; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Promoter Regions, Genetic; Proportional Hazards Models; Reference Values; Snake Venoms; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Snake Venoms; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Snake Venoms; Treatment Outcome; Young Adult | 2015 |
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cohort Studies; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Integrin alphaVbeta3; Male; Middle Aged; Neoplasm Staging; Prognosis; Receptors, Vitronectin; Smad2 Protein; Snake Venoms; Survival Rate; Young Adult | 2016 |
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Procarbazine; Snake Venoms; Temozolomide; Treatment Failure; Tumor Suppressor Proteins; Young Adult | 2016 |
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Peptides, Cyclic; Quality of Life; Snake Venoms; Treatment Outcome | 2008 |
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Combined Modality Therapy; Confidence Intervals; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Immunohistochemistry; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neurosurgical Procedures; Probability; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Risk Assessment; Snake Venoms; Survival Analysis; Temozolomide; Treatment Outcome | 2010 |
Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival; Endpoint Determination; Female; Glioblastoma; Humans; Immunotherapy; Integrins; Karnofsky Performance Status; Male; Middle Aged; Recurrence; Snake Venoms | 2012 |
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Integrins; Male; Middle Aged; Snake Venoms; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2012 |
Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial.
Topics: Angiogenesis Inhibitors; Blood Flow Velocity; Blood Volume; Brain Neoplasms; Disease Progression; Echo-Planar Imaging; Glioblastoma; Glioma; Humans; Magnetic Resonance Angiography; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Peptides, Cyclic; Snake Venoms | 2004 |
22 other study(ies) available for cilengitide and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme.
Topics: Animals; Cell Line, Tumor; Glioblastoma; Integrin alpha5beta1; Integrin alphaVbeta3; Mice; Models, Molecular; Molecular Targeted Therapy; Oligopeptides; Peptidomimetics; Protein Conformation; Proto-Oncogene Proteins c-mdm2 | 2018 |
Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report.
Topics: Brain Neoplasms; Child; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Prognosis; Temozolomide | 2023 |
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Gene Expression Profiling; Glioblastoma; Glucose Transporter Type 3; Humans; Integrin alphaVbeta3; Kaplan-Meier Estimate; Mice; Mice, Nude; Signal Transduction; Snake Venoms; Transcriptome; Xenograft Model Antitumor Assays | 2017 |
Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bevacizumab; Carmustine; Chemoradiotherapy; Dasatinib; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Photons; Progression-Free Survival; Propensity Score; Quinazolines; Radiotherapy Dosage; Radiotherapy, Conformal; Snake Venoms; Supratentorial Neoplasms; Temozolomide; Young Adult | 2018 |
Novel Integrin αvβ3-Specific Ligand for the Sensitive Diagnosis of Glioblastoma.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Gene Knockout Techniques; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Integrin alphaVbeta3; Ligands; Male; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Oligopeptides; Optical Imaging; Protein Binding; Snake Venoms; Transfection; Xenograft Model Antitumor Assays | 2019 |
Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Separation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Flow Cytometry; Glioblastoma; Humans; Inhibitory Concentration 50; Male; Middle Aged; Promoter Regions, Genetic; Snake Venoms; Temozolomide; Tumor Suppressor Proteins | 2013 |
Cilengitide in glioblastoma: when did it fail?
Topics: Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Snake Venoms; Temozolomide; Tumor Suppressor Proteins | 2014 |
The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway.
Topics: Animals; Animals, Newborn; Antibodies, Neutralizing; Brain Neoplasms; Cell Line, Tumor; Cells, Cultured; Glioblastoma; Hepatocytes; Humans; Immunoblotting; Immunohistochemistry; Integrins; Mice, Inbred C57BL; Mice, Knockout; Naphthyridines; Peptides, Cyclic; Receptors, Aryl Hydrocarbon; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Snake Venoms; Sulfonamides; Transforming Growth Factor beta | 2016 |
Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease L1CAM-stimulated glioblastoma cell motility and proliferation.
Topics: Aniline Compounds; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Focal Adhesion Kinase 1; Glioblastoma; Humans; Integrin alphaVbeta3; Neural Cell Adhesion Molecule L1; Pyrimidines; Receptors, Fibroblast Growth Factor; Receptors, Vitronectin; Snake Venoms | 2016 |
Acute Temporal Changes of MRI-Tracked Tumor Vascular Parameters after Combined Anti-angiogenic and Radiation Treatments in a Rat Glioma Model: Identifying Signatures of Synergism.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Glioblastoma; Humans; Magnetic Resonance Imaging; Rats; Snake Venoms; Time Factors | 2017 |
Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway.
Topics: Actins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Cytoskeleton; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Endothelial Cells; Focal Adhesion Kinase 1; Glioblastoma; Humans; Oncogene Protein v-akt; Phosphorylation; Promoter Regions, Genetic; Snake Venoms; src-Family Kinases; Swine; Temozolomide; Tight Junctions; Tumor Suppressor Proteins | 2008 |
Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.
Topics: Animals; Apoptosis; Cell Adhesion; Cell Line, Tumor; Endothelial Cells; Glioblastoma; Humans; Integrin alphaVbeta3; Oligonucleotide Array Sequence Analysis; Radiation-Sensitizing Agents; Rats; Rats, Wistar; Receptors, Vitronectin; Snake Venoms; Transcription Factor RelA; Xenograft Model Antitumor Assays | 2009 |
Cilengitide: does it really represent a new targeted therapy for recurrent glioblastoma?
Topics: Antineoplastic Agents; Glioblastoma; Humans; Neoplasm Recurrence, Local; Snake Venoms | 2009 |
Will integrin inhibitors have proangiogenic effects in the clinic?
Topics: Animals; Glioblastoma; Humans; Integrins; Neovascularization, Pathologic; Snake Venoms | 2009 |
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Benzodiazepines; Biomedical Research; Brain Neoplasms; Carboxymethylcellulose Sodium; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Interferon Inducers; Male; Middle Aged; Poly I-C; Polylysine; Receptors, AMPA; Snake Venoms; Survival Rate; Temozolomide; Treatment Outcome; United States; Young Adult | 2010 |
Integrins as target: first phase III trial launches, but questions remain.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Glioblastoma; Humans; Integrins; Neoplasms; Snake Venoms | 2010 |
What role should cilengitide have in the treatment of glioblastoma?
Topics: Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Snake Venoms; Temozolomide | 2010 |
Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Industry; Glioblastoma; Humans; Integrins; Oligopeptides; Snake Venoms; Treatment Outcome | 2011 |
Combination therapy of cilengitide with belotecan against experimental glioblastoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Snake Venoms; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2013 |
Integrin control of the transforming growth factor-β pathway in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Integrins; Mice; Mice, Nude; Mink; Neural Pathways; Snake Venoms; Transforming Growth Factor beta1 | 2013 |
Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Snake Venoms; Treatment Outcome | 2006 |
alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Adhesion; Cell Division; Collagen; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Integrins; Medulloblastoma; Mice; Mice, Nude; Peptides, Cyclic; Receptors, Vitronectin; Snake Venoms; Tenascin; Tumor Cells, Cultured; Vitronectin | 2002 |